IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) | PAR 23 257

Opportunity Information: Apply for PAR 23 257

The IDeA Clinical and Translational Research Development (CTR-D) Award (P20 - Clinical Trial Optional), Funding Opportunity Number PAR-23-257, is a National Institutes of Health (NIH) discretionary grant program in the health funding area (CFDA 93.859). Its core goal is to grow and strengthen clinical and translational research capacity in IDeA-eligible states and jurisdictions, which are places that historically receive lower levels of NIH research funding. In practical terms, the program is designed to help these states build the people, systems, and partnerships needed to compete more successfully for future external research support, especially NIH and other extramural clinical and translational research funding.

The FOA supports cooperative agreement-based efforts that organize statewide and/or multi-state regional networks. These networks are expected to do three main things. First, they must develop or enhance research infrastructure and the human resources required to conduct high-quality clinical and translational research, which can include shared cores, data and informatics capabilities, clinical research support services, regulatory and compliance assistance, workforce training, and other capacity-building functions that make research feasible and efficient. Second, the program aims to strengthen clinical and translational research that responds to the real health needs and challenges experienced by populations in IDeA states and jurisdictions, encouraging projects and programs that are relevant to local disease burdens, rural and underserved populations, and other region-specific priorities. Third, it emphasizes collaboration: applicants are expected to foster and coordinate teamwork within the IDeA-CTR network itself and also build productive connections with other institutions, helping investigators work across disciplines and organizations and making it easier to launch competitive, multi-site clinical and translational research efforts.

Eligibility is broad and includes many types of domestic U.S. organizations and governments. Eligible applicants listed in the opportunity include state governments; county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American Tribal Governments (other than federally recognized), and U.S. territories or possessions.

At the same time, the FOA is clear about foreign restrictions. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply. Non-domestic components of U.S. organizations are also not eligible to apply, and foreign components as defined by the NIH Grants Policy Statement are not allowed. This keeps the program focused on building domestic capacity within IDeA-eligible U.S. states and jurisdictions.

Key administrative details in the provided source include an original closing date of 2025-10-09 and an award ceiling of $1,500,000. The mechanism is described as a cooperative agreement support model, which generally indicates more substantial NIH involvement or partnership during the project period compared with a standard grant. The FOA is also labeled "Clinical Trial Optional," meaning applicants may propose clinical trials if they are appropriate to the program goals, but a clinical trial is not required for eligibility.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859.
• This funding opportunity was created on 2023-08-29.
• Applicants must submit their applications by 2025-10-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 23 257

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: